Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics™, is pleased to announce...
Genetics can influence every area of our biology, including how we respond to psychedelics. Understanding the roles that our genes play is essential when...
The article Cybin Buys License to Mindset Pharma’s Psychedelic Compounds was originally published on Microdose. Cybin Obtains Exclusive License to a...
Genetics can influence every area of our biology, including how we respond to psychedelics. Understanding the roles that our genes play is essential when...
Licensing Subset of Mindset’s Family 1 Intellectual Property Underscores Strength of Mindset’s Portfolio and Business StrategyTORONTO, Sept. 27, 2022...
People who stacked psilocybin with other substances like these were less likely to drink alcohol or smoke cigarettes as well. The post Psychedelic Stacking...
Traditional psychedelics have shown great potential for treating issues like depression, anxiety, PTSD, and addiction. Psilocybin and MDMA will likely...
TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery...
Big money is starting to take a more public interest in the science of psychedelics, which makes even the biggest skeptics take notice. The post Big...
TORONTO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery...